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Background: pneumococcal conjugate vaccines (pCV) reduce naso-
pharyngeal carriage of vaccine type (Vt) pneumococci, an important driver 
of vaccine programs’ overall benefits. the dosing schedule that best reduces 
carriage is unclear.
Methods: We performed a systematic review of english language publications 
from 1994 to 2010 (supplemented post hoc with studies from 2011) reporting 
pCV effects on Vt carriage to assess variability in effect by dosing schedule.
Results: We identified 32 relevant studies (36 citations) from 12,980 cita-
tions reviewed. twenty-one (66%) evaluated pCV7; none used pCV10 
or pCV13. Five studies evaluated 2 primary doses and 13 three primary 
doses. After the first year of life, 14 evaluated 3-dose primary series with 
pCV booster (3+1), seven 3 doses plus 23-valent polysaccharide booster 
“3+1ppV23,” five “3+0,” four “2+1,” three “2+1ppV23” and two “2+0.” 
Four studies directly compared schedules. From these, 3 primary doses 
reduced Vt carriage more than 2 doses at 1–7 months following the series 
(1 study significant; 2 borderline). In a study, the 2+1 schedule reduced Vt 
carriage more than 2+0 at 18, but not at 24 months of age. One study of a 
23-valent pneumococcal polysaccharide vaccine booster showed no effect. 
All 16 clinical trials with unvaccinated controls and 11 observational stud-
ies with before-after designs showed reduction in Vt carriage.
Conclusions: the available literature demonstrates Vt-carriage reduction 
for 2+0, 2+1, 3+0 and 3+1 pCV schedules, but not for 23-valent pneu-
mococcal polysaccharide vaccine booster. Comparisons between schedules 
show that 3 primary doses and a 2+1 schedule may reduce carriage more 
than 2 primary doses and a 2+0 schedule, respectively.
Key Words: pneumococcal conjugate vaccine, immunization schedule, 
nasopharyngeal carriage, nasopharyngeal colonization, systematic review
(Pediatr Infect Dis J 2014;33:S152–S160)
Streptococcus pneumoniae (pneumococcus) colonizes the human nasopharynx, particularly in young children, and is part of the 
normal nasopharyngeal (np) bacterial flora.1 Although pneumococ-
cal colonization is usually asymptomatic, in some cases, it progresses 
to a disease state, with spread from the nasopharynx resulting in 
sinusitis, otitis media, pneumonia and invasive diseases, such as bac-
teremia and meningitis.2 Vaccines targeting pneumococcus have been 
shown to differ in their protective efficacy against np carriage. the 
23-valent pneumococcal polysaccharide vaccine (ppV23), licensed 
in 1983, protects against invasive pneumococcal disease (IpD, infec-
tion of a normally sterile body site) in adults,3 but not against np 
carriage.4 pneumococcal conjugate vaccine (pCV), first licensed for 
infant use in 2000, protects against invasive and non-IpD5 and against 
acquisition and density of vaccine serotype (Vt) np carriage.6,7 pCV 
use among children leads to simultaneous decreases in Vt IpD and 
carriage in non-vaccinated age groups (eg, adults), demonstrating 
that infant and toddler np carriage is an important driver of pneumo-
coccal transmission in the household and community.8 Based on the 
precondition of np carriage for development of disease and its role 
in transmission, the effect of pCV on Vt carriage is important and 
may be used along with other data to infer pCV impact on disease.
pCV7 and pCV10 were initially licensed for 3 primary doses 
plus a booster (3+1 schedule), and pCV7, pCV10 and pCV13 were 
later granted licenses in europe and elsewhere for schedules using 
2 primary doses plus a booster (2+1).9–11 However, we lack a clear 
understanding of the full impact of reduced-dose schedules rela-
tive to 3+1. One previous report reviewed clinical trials, cohort and 
case-control studies that made direct comparisons of various pCV 
schedules within each study; however, only 2 studies from the large 
body of evidence on pCV and np-carriage effects met the report’s 
inclusion criteria for np-carriage evaluations.12
We examined the larger set of literature regarding pCV dos-
ing schedules to address the following key policy questions regarding 
direct effects of vaccine on Vt carriage: (1) What is the evidence that a 
3-dose primary series is superior or inferior to a 2-dose primary series? 
(2) If only 3 doses are used, is there any evidence to prefer a 2+1 or 
a 3+0 schedule? (3) What is the evidence that a schedule including a 
booster dose is superior to one without a booster dose? and (4) Is there 
evidence to support the choice of pCV or ppV23 as a booster dose?
METHODS
Literature Search
this analysis is part of a larger project describing the impact 
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pneumonia and indirect effects.13–16 Details on the literature search 
terms and methods used in this systematic review are described else-
where (see methods Appendix17). In brief, a systematic literature 
review was performed to collect all available english language data 
published from January 1994 to September 2010 (supplemented 
post hoc with studies from 2011) on the effect of various pCV vac-
cination schedules among immunized children on immunogenicity, 
np colonization, IpD, pneumonia and on indirect effects among 
unvaccinated populations. Articles published in 14 databases, 
from ad hoc unpublished sources and abstracts from meetings 
of the International Symposium on pneumococci and pneumo-
coccal Disease (1998–2010) and the Interscience Conference on 
Antimicrobial Agents and Chemotherapeutics (1994–2010), were 
searched. We included all randomized controlled clinical trials, 
nonrandomized trials, surveillance database analyses and observa-
tional studies of any pCV schedule on 1 or more outcomes of inter-
est. Studies were included for abstraction if ppV23 was used as a 
booster dose, but not if used as a primary dose. titles and abstracts 
were reviewed twice and those with relevant content on 1 of the 5 
outcomes (immunogenicity, carriage, invasive disease, pneumonia 
and indirect effects) underwent full review using a standardized 
data collection instrument. We did not search non-english language 
literature because of the low likelihood they would have on relevant 
data for this project. Details on the search methods are provided 
elsewhere (methods Appendix17).
Data Abstraction
Citations recovered through the literature search went 
through several stages of independent review to determine their 
eligibility, as described elsewhere (methods Appendix17). Citations 
meeting inclusion criteria were categorized on an outcome specific 
basis into “study families,” where each family included abstracts 
or publications generated from a single protocol, population, sur-
veillance system or other data collection system relevant to that 
outcome. Investigators identified primary data from the individual 
studies making up each study family for inclusion in the analysis. 
the primary data were selected as the most current and complete 
data available for that study family. In some cases, these data were 
drawn from more than 1 publication within a family. We also defined 
“study arms” as a group of children distinguished by immunization 
schedule or pCV product.
We abstracted core information on the following: number of 
children in a “study arm”; pCV manufacturer, valency and conju-
gate protein; co-administered vaccines; country; age at each dose 
and date of study and publication. Additional data abstracted for the 
direct effect of pCV on Vt np carriage included age at each np 
specimen collection.
Inclusion and Exclusion Criteria
We included data published from randomized controlled tri-
als, nonrandomized trials, surveillance databases and observational 
studies of pCV schedules on Vt carriage. We included all pCV 
products (denoted as pCV with a number indicating the valency, 
eg, pCV7). We excluded studies with all vaccination series begin-
ning after 12 months of life, studies that only reported data before 
or after pCV introduction but not for both periods and studies that 
did not report direct pCV effects on Vt carriage.
Pneumococcal Vaccine Dosing Schedules
We included pCV schedules with 2 primary doses only 
(2+0), 2 primary doses plus a pCV booster (2+1) or a ppV23 booster 
(2+1ppV23), 3 primary doses only (3+0) and 3 primary doses plus a 
pCV booster (3+1) or a ppV23 booster (3+1ppV23).
Data Analysis
Because the included studies used various designs and meth-
ods, we were unable to perform a meta-analysis. thus, we summa-
rized the data across studies in descriptive analyses to provide an 
overview of the amount and variability of data by schedule. each 
study was divided into arms, defined as a unique combination of 
vaccine schedule, age at np specimen collection and vaccine prod-
uct used. Studies could have multiple arms. Vt was defined as each 
study defined it, based on the product used. no studies included 
pCV products with serotype 19A; none classified 19A as Vt. two 
pCV7 studies included serotype 6A as a Vt.18,19 We defined percent 
Vt carriage as the percentage of children sampled who carried a Vt 
strain, except in 7 citations that only reported percent of pneumococ-
cal isolates that were Vt, in which case this percent was used.7,20–25
For clinical trials, we abstracted the difference in Vt-car-
riage prevalence with confidence intervals (CI) between vaccinated 
children and controls. If not reported, we calculated the difference 
in carriage between vaccinated children and controls. We separated 
clinical trials into those that directly compared np effects of vari-
ous schedules and trials that evaluated effects only between a given 
schedule and unvaccinated controls. We separated these latter trials 
into those that examined carriage early (during the first year of life 
or prior to any booster dose given in the study) and late (after the 
first year of life or after any booster dose given in the study).
For pre- and postvaccine introduction observational studies 
among age groups targeted for vaccination, we calculated percent 
change in Vt carriage by defining the baseline prevalence as the 
mean of all data points reported prior to introduction. In cases where 
only the postintroduction Vt-carriage prevalence over a period was 
provided, we calculated percent change from the baseline preva-
lence to the reported prevalence and assigned it to the median year 
of the date range provided. When possible, the year of vaccine intro-
duction was excluded from these calculations. We used microsoft 
Access 2003 and 2007 (microsoft Corporation, Redmond, WA) for 
data abstraction and SAS 9.2 and 9.3 (SAS Institute Inc., Cary, nC) 
for analyses. Statistical significance was defined as P < 0.05.
RESULTS
Description of Included Studies
Of 12,980 citations reviewed, 145 had carriage data; of these, 
36 met inclusion criteria for Vt carriage among children targeted 
to receive the vaccine (Fig. 1).4,7,18–51 these 36 citations represented 
32 study families with 4 supplemental citations. Among the 32 
studies, 25 (78%) were published in 2003 or later; 17 (53%) were 
from europe or north America (table 1).52 Seven (22%) evaluated 
children at high risk for pneumococcal disease, such as children 
with HIV or sickle cell disease, indigenous children or children 
with acute pneumonia or otitis media. twenty-one (66%) studies 
evaluated pCV7; no studies evaluated pCV10 or pCV13.
Direct Comparisons of Dosing Schedules Within 
Studies: Clinical Trials
Among the 32 studies, 4 directly compared Vt-carriage 
reduction among dosing regimens. the first study, conducted in 
Fiji, compared 0, 1, 2 and 3 pCV7 doses (given at 14 weeks, 6 and 
14 weeks or 6, 10 and 14 weeks, respectively) with and without a 
ppV23 booster at 12 months.4 the investigators found a significant 
difference in Vt-carriage prevalence between the 2- and 3-dose 
groups at 9 months; the 3-dose group had significantly less Vt car-
riage [odds ratio 0.30 (CI: 0.09–0.9)]. At 6, 12 and 17 months of 
age, Vt carriage among the 2- and 3-dose groups was not signifi-
cantly different. the receipt of a ppV23 booster showed no effect 
on Vt carriage, as no difference in Vt carriage at 17 months was 
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seen between those who did and did not receive the ppV23 booster 
in each pCV dosing group.4 the second study, conducted in the 
Gambia, compared 1, 2 and 3 pCV7 doses (given at 2 months, 2 
and 3 months and 2, 3 and 4 months); all children received a ppV23 
booster at 10 months.44 At 11 months, 3 pCV doses showed a bor-
derline significant reduction in Vt carriage compared with 2 pCV 
doses (10.0% vs. 16.7%, P = 0.056). However, at 5 and 15 months, 
the Vt carriage prevalence was not significantly different among 
children who received 2 and 3 doses.44 the third study, conducted in 
Israel with pCV7, compared a 3+1 schedule (2, 4, 6 and 12 months) 
with 2+1 (4, 6 and 12 months) and 0+2 (12 and 18 months) sched-
ules.19 Between 7 and 12 months of age (prebooster), the mean 
Vt prevalence was nonsignificantly lower in the 3+1 group when 
compared with the 2+1 group (22.6% vs. 28.4%, P = 0.089). the 
0+2 group between 7 and 12 months, that is, before children were 
vaccinated, had a mean Vt prevalence of 35.2%, which was signifi-
cantly higher than the 3+1 group (P < 0.001). Between 13 and 18 
months (ie, after the booster dose) and between 19 and 30 months, 
the 3+1 and 2+1 groups had equivalent Vt prevalence, but both 
groups had significantly lower Vt prevalence than the 0+2 group.19 
A fourth study, conducted in the netherlands, compared children 
who received pCV7 at 2 and 4 months (2+0); 2, 4 and 11 months 
(2+1) and unvaccinated controls.48 At 12, 18 and 24 months of 
age, children in the 2+0 and 2+1 groups had significantly less Vt 
carriage than unvaccinated controls. Although children in the 2+1 
group had a significantly lower prevalence of Vt carriage at 18 
months (16%) than the 2+0 group (24%, P = 0.01), no difference 
was found at 24 months.48
Early Assessment of VT Carriage During 
First Year of Life: Clinical Trials
ten clinical trials evaluated 2- and 3-dose primary regimens 
during the first year of life compared with control subjects who 
received either placebo or no vaccine. two trials examined both 
regimens4,19; 1 trial examined only a 2-dose regimen48 and 7 studies 
examined only a 3-dose regimen (Fig. 2).7,27,29,38,43,46,50 these 10 tri-
als included 23 study arms. All 5 arms evaluating a 2-dose primary 
series found reductions in Vt-carriage prevalence among pCV 
recipients compared with controls, although only 1 arm reached 
statistical significance. Of 18 arms, 17 with 3-dose primary regi-
mens observed reductions in Vt carriage; 11 arms were statisti-
cally significant. One 3-dose primary series arm (merck, pCV7) 
observed a nonsignificant increase of Vt-carriage prevalence at 7 
months of age.50
two trials examined the Vt-carriage effect of 3 primary 
doses but provided results that could not be compared with other 
studies. One, a clinical trial in Iceland, examined 81 children who 
received pCV8 conjugated to diphtheria or tetanus toxoid given in 
3 primary doses (3, 4 and 6 months) and 40 unvaccinated controls.34 
Swabs were collected at 3, 4, 6, 7, 10, 14 and 18 months. For swabs 
at ages ≤6 months, Vt carriage was not significantly different 
between controls (21%) and vaccinees (18%, P = 0.5). Vaccinees 
were then given either a pCV8 booster or a ppV23 booster at 13 
months, but results from swabs at ages >6 months were not reported 
separately for those who received pCV8 and ppV23 boosters and 
thus are not presented here.34 the other study, a trial conducted in 
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or 6 weeks of age with subsequent doses at 10 and 14 weeks and 
found no significant differences in Vt carriage at 18 and 36 weeks 
among the regimens.51
Late Assessment of VT Carriage After the First 
Year of Life: Clinical Trials
thirteen clinical trials (14 citations) assessed Vt car-
riage with samples taken after the first year of life (Fig. 3). two 
trials examined 2+0 schedules4,48; one 2+148; two 2+1ppV234,42; 
four 3+04,27,37,41; five 3+17,30,39,45,46,50 and four 3+1ppV23.4,29,35,42 
Among the 29 arms reported in these 13 studies, 28 showed reduc-
tion in Vt compared with control subjects; 15 arms were statisti-
cally significant (Fig. 3). One arm conducted among South African 
children with HIV who received a 3+0 pCV9 schedule had a non-
significant increase in Vt carriage when compared with controls.37
Impact of Vaccine Introduction on VT Carriage: 
Observational Studies
Results by schedule from 11 observational, pre/post-
vaccine introduction studies (13 citations) are shown in 
Figure 4.18,20–26,28,31,36,47,49 All observational studies used pCV7. none 
examined a 3+0 schedule. two observational studies examined 2+1 
schedules. One conducted in england with national introduction with 
a catch-up campaign showed a statistically significant reduction.18 A 
study in Switzerland with private-market introduction among chil-
dren <2 years of age with acute otitis media or pneumonia also showed 
reduction; statistical significance was not reported.21 Five studies 
in the united States,22,24,25,31,47,49 2 in France20,28 and 1 in  portugal23 
evaluated 3+1 schedules: all showed reductions in Vt  carriage. 
Five studies were statistically significant20,22,23,28,31 and 3 studies 
(4 citations) did not report statistical significance.24,25,47,49 Finally, 1 
study among Australian Aboriginal children showed a significant 
reduction in Vt carriage following a 3+1ppV23 schedule,36 while a 
British study among children with sickle cell disease found a nonsig-
nificant reduction in Vt carriage following a 3+1ppV23 schedule.26
Additional observational studies met inclusion criteria 
but were not comparable to other studies because of their unique 
designs. A cohort study from Korea evaluated the effect of a 3+1 
schedule (given at 2, 4, 6 and 16.5 months), following pCV7 pri-
vate-market introduction.33 this study compared vaccinated chil-
dren in daycare from a highly vaccinated region to unvaccinated 
children in daycare from a region with low vaccination rates.33 
At mean ages of 35.2 months for vaccinated and 42.3 months for 
unvaccinated children, Vt carriage was found in 4 (2%) of 200 vac-
cinated and 33 (16.5%) of 200 unvaccinated children.33 An open-
label, prospective study in mexico evaluated Vt-carriage acquisi-
tion in children receiving either 3 pCV7 doses (given between 6 
weeks and 6 months) or 2 doses (given between 7 and 11 months); 
no unvaccinated controls were included in the study.32 Vt acquisi-
tion decreased over time in both the 2- and 3-dose primary regi-
mens, but the groups were not directly compared. An observational 
follow-up study to a clinical trial in the philippines compared chil-
dren with pneumonia between 6 weeks and 23 months old, who had 
received pCV11 or placebo at a median age of 7, 12 and 16 weeks.40 
Vt was reduced in the pCV11 group versus placebo; quantitative 
results were not provided.40
Finally, a pre/postintroduction study from France also 
included a sub-analysis examining the effect of the booster dose.28 
pCV7 was licensed in France in 2001 and reimbursed for chil-
dren with high-risk medical or living conditions in 2003 using a 
schedule of 2, 3 and 4 months with a booster in the second year of 
life.53 In this study, children 6–24 months with acute otitis media 
in French day care centers were enrolled in annual cross-sectional 
surveys from 2001 to 2006.28 Among children >1 year of age dur-
ing all years of the study, Vt carriage was 44.4% in unvaccinated 
children, 23.9% in children vaccinated without a booster dose and 
11.8% in children vaccinated with the booster dose.28
DISCUSSION
We found that all schedules reviewed—2+0, 2+1, 
2+1ppV23, 3+0, 3+1 and 3+1ppV23—reduced carriage of Vts 
of pneumococcus compared with no pCV. However, the strength 
of evidence supporting each schedule varies and effects differ 
among the schedules. First, in studies with direct comparisons 
of 2 versus 3 primary doses, 3 doses result in a greater reduc-
tion in Vt carriage compared with 2 doses at 1–7 months follow-
ing the primary series.4,19,44 However, measurable differences in 




  1994–1998 3 (9)
  1999–2002 4 (13)
  2003–2006 5 (16)
  2007–present 20 (63)
Study type
  Clinical trial 19 (59)
  Pre-post trend survey 11 (34)
  Other observational* 2 (6)
United Nations Region52
  Africa 7 (22)
  Asia 5 (16)
  Europe 11 (34)
  Latin America 1 (3)
  North America 6 (19)
  Oceania 2 (6)
High risk
  None 25 (78)
  HIV-infected 1 (3)
  Sickle cell disease 1 (3)
  Indigenous 3 (9)
  Acute illness† 2 (6)
Dosing schedule‡
  Carriage assessed during first year of life§
   2 primary dose series 5 (16)
   3 primary dose series 13 (41)
  Carriage assessed after first year of life¶
   2 + 0 2 (6)
   2 + 1 4 (13)
   2 + 1PPV23 3 (9)
   3 + 0 5 (16)
   3 + 1 14 (44)
   3 + 1PPV23 7 (22)
Product‖
  PCV7-Wyeth/Pfizer 21 (66)
  PCV9-Wyeth 4 (13)
  PCV11-Sanofi 2 (6)
  Other PCV** 5 (16)
Type of vaccine introduction
  Available through study 20 (63)
  National immunization program 5 (16)
  High-risk introduction 3 (9)
  Private introduction 3 (9)
  Private and high-risk introduction 1 (3)
*One cohort study33 and 1 open-label, prospective, observational trial.32
† Acute otitis media or pneumonia at time of NP swab collection.
‡‡Percentages add up to >100%, as studies may have multiple dosing schedules and 
may have assessed carriage both during and after the first year of life.
§Total study arms with carriage specimens during the first year of life (n = 18).
¶Total study arms with carriage specimens after the first year of life (n = 35).
‖Products are listed as PCV, valency and manufacturer name.
**Includes PCV4-Sanofi, PCV5-Wyeth, PCV7-Merck, PCV8-Sanofi and PCV11-
Glaxo SmithKline.
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Vt-carriage reduction between 2 and 3 primary doses are not seen 
on further follow up following primary vaccination in schedules 
with pCV boosters,19 ppV23 boosters4,44 or no boost.4 Differences 
between the schedules are difficult to discern when comparing 
the impact of 2- and 3-dose primary series between studies rather 
than within studies.
Very little evidence is available on Vt-carriage prevalence 
after the first year of life in children who received a 2-dose sched-
ule without a booster dose. Both clinical trials that evaluated 2+0 
schedules after the first year of life demonstrated reductions in 
Vt carriage.4,48 However, in 1 of these studies, the 2+1 schedule 
reduced Vt carriage more than the 2+0 schedule at 1 of 3 time 
points, suggesting that the 2+1 schedule may be better than the 
2+0.48 Furthermore, there is no evidence regarding effect of 2+0 
schedules on Vt carriage from observational studies or for long-
term effects of this schedule since no country is using this schedule. 
Concerns regarding the immunogenicity of 2+0 schedules and the 
lack of evidence regarding the impact of 2+0 schedules on IpD, 
pneumonia and indirect effects have precluded its use in national 
immunization programs to date.
more evidence is needed regarding the optimal timing of the 
doses in a 3-dose schedule, but available evidence supports the use 
of both 2+1 and 3+0 schedules. While no published studies directly 
compare the impact of 2+1 and 3+0 schedules on Vt carriage, 
both schedules reduce Vt carriage compared with no pCV use. A 
study of 2+1, 3+0 and 3+1 schedules using pCV7 from Israel was 
done and has been published in part.19,54 Results suggest that the 
2+1 schedule results in similar Vt-carriage prevalence to 3+1 when 
Vt-carriage prevalence is sampled after the booster doses; however, 
2+1 appears to be inferior to 3+1 prior to the booster dose. Addition-
ally, this study directly compared 3+0 and 3+1 schedules and showed 
no difference in Vt-carriage prevalence. these data suggest that 2+1 
and 3+0 schedules may have similar effects on Vt carriage after the 
first year of life, but these schedules were not directly compared in 
this study. It is important to note that data supporting 2+1 schedules 
come from a clinical trial and 2 observational studies in europe (the 
netherlands,48 england18 and Switzerland),21 whereas data support-
ing a 3+0 schedule come from clinical trials in middle income and 
developing countries (philippines,40,41 Fiji,4 the Gambia27 and South 
Africa).37 While both 3+0 and 2+1 schedules appear to be effective, 
differences between 2+1 and 3+0 schedules may exist that are rele-
vant to settings with particular pneumococcal transmission patterns, 
burden of disease or colonization. For example, vaccine programs 
serving populations with disease early in life, heavy transmission 
and young age of transmitters may prefer 3+0 schedules; however, 
the data in our review do not provide a conclusive determination of 
which schedule is optimal for each of these settings.
Some evidence suggests that schedules with pCV boosters 
may provide additional reductions in Vt carriage.28,48 the avail-
able evidence does not support the use of schedules with ppV23 
boosters for improving np-carriage reductions. While no studies 
directly compared pCV and ppV23 boosters, a Fijian study com-
pared schedules with and without ppV23 boosters and showed no 
benefit of 2+1ppV23 and 3+1ppV23 schedules compared with 2+0 
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Determining the relative benefit for np-carriage reductions 
of 1 schedule over another is difficult. limited data are available 
from studies with direct comparisons between schedules. Few are 
conducted in regions where child mortality is high, and some stud-
ies were in the setting of catch-up campaigns, which would blur the 
measured effect of the primary schedule. these limitations should 
be considered when assessing the potential benefits of particular 
schedules. For example, while 2+1 schedules reduced Vt carriage 
in 2 observational studies, it is important to note that 1 study was 
conducted among vaccinated children in the setting of a private-
market introduction,21 where vaccinated children may have lower 
inherent risk of colonization, and 1 study was conducted among all 
children <5 years old in the setting of a national immunization pro-
gram with a catch-up campaign.18 Furthermore, only 7 np studies 
evaluated pCV schedule impact in children at high risk for coloni-
zation and disease; the only study to specifically evaluate children 
with HIV failed to show efficacy of a 3+0 schedule on Vt car-
riage.37 none of the studies included evaluated pCV10 or pCV13, 
which are currently being used in national immunization programs. 
However, a study in France, conducted in the year following the 
switch from pCV7 to pCV13, showed a significant reduction in the 
additional 6 serotypes included in pCV13 among children partially 
and fully vaccinated with pCV13 when compared with those vac-
cinated with pCV7.55 this study was not included in this analysis 
due to a lack of pre-pCV introduction data for pCV13 serotypes.55
this analysis focused on Vt carriage and did not address the 
effect of dosing schedules on all pneumococcal carriage or non-Vt 
carriage, as the impact on Vt carriage is the most important fac-
tor for policy makers when deciding which dosing schedules to rec-
ommend. most studies show that pCV does not affect the overall 
prevalence of all-serotype pneumococcal carriage,4,7,18–23,27,31,36,39,41,43 
although some show a reduction at some or all time points.19,25,28,48 
Additionally, most studies show that non-Vts increase in prevalence 
following pCV,4,7,18,19,23,27,28,31,36,38,39,42,48 although a few studies show no 
change at some or all time points.4,7,19 many, but not all, non-Vts 
have lower invasive potential than most Vt strains, meaning that they 
are less likely to cause IpD if carried,18 and invasive potential does 
not appear to change with time47,56 or vaccine introduction.47 thus, 
the potential for many replacing serotypes to cause IpD is not as high 
as for serotypes included by currently available pCV products.
this analysis has several strengths and limitations. the 
strengths of this analysis are its comprehensive nature with the 
diversity of countries and study designs included. Very few np 
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of the supporting evidence for each of these regimens to be consid-
ered. However, the analysis is limited because fully differentiating 
the relative magnitude of the impact on Vt carriage of each sched-
ule is not possible. Geographic region, socioeconomic level and 
other factors affect carriage of pneumococci and thus confound our 
ability to compare magnitudes of impact across studies. Addition-
ally, we were unable to account for vaccine coverage in the target 
populations or the presence of catch-up campaigns due to limited 
information in the study reports.
In conclusion, 2+0, 2+1, 3+0 and 3+1 schedules all reduce 
pneumococcal Vt carriage. Importantly, the evidence indicates 
that 3 primary doses may reduce Vt carriage more than 2 pri-
mary doses; that both 2+1 and 3+0 schedules are effective; pCV 
booster doses may be helpful, especially in the setting of 2 primary 
doses and the use of ppV23 boosters after a pCV schedule does 
not further reduce Vt carriage. Our analysis supports recent rec-
ommendations by the pan American Health Organization and the 
World Health Organization for the use of 3 doses of pCV and the 
acceptability to be administered either as 3+0 or 2+1 schedule.57,58 
However, np carriage is only part of the picture, and the effect 
of each schedule on IpD, pneumonia, immunogenicity and indi-
rect effects in the context of local epidemiology and programmatic 
considerations should be considered by public health when recom-
mending and countries when choosing a schedule.
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